← All trials
NCT05104424
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 26, 2021
- Primary completion
- Aug 26, 2022
- Completion date
- Oct 1, 2022
- First posted
- Nov 3, 2021
- Last posted
- Nov 3, 2021
- Enrollment
- 22
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Government of Saudi ArabiaLead sponsor
- Government of Saudi ArabiaReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.